Hari Kumar
Chairman at Kinarus AG
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alexander Bausch | M | - |
Kinarus AG
 Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Thomas Theriault | M | 61 |
Bullet Biotechnology, Inc.
 Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | 13 years |
| Diego Fonstad | M | - |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | 13 years |
| James R. Swartz | M | - |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | 13 years |
| Roger Meier | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Samuel Saks | M | 69 |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | 12 years |
| James Mulé | M | 72 |
Translational Research In Oncology
| - |
| Silvio Inderbitzin | M | 59 |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Dennis Joseph Slamon | M | 75 |
Translational Research In Oncology
| - |
| Subhasis Roy | M | 55 |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Thierry Fumeaux | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | 3 years |
| Matthew Wright | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Eugene Tierney | M | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Claudia Berger | F | - |
Kinarus AG
Kinarus AG Pharmaceuticals: MajorHealth Technology Part of Kinarus Therapeutics Holding AG, Kinarus AG is a Swiss clinical stage pharmaceutical company that focuses on novel treatments to patients suffering from viral, respiratory and ophthalmic diseases. The company is based in Basel, Switzerland. The company was founded in 2017 by Alexander Bausch, Roger Meier. Alexander Bausch has been the CEO since 2017. Kinarus was acquired by Perfect Holding SA on June 03, 2022. | - |
| Julie Vose | F | - |
Bullet Biotechnology, Inc.
Bullet Biotechnology, Inc. BiotechnologyHealth Technology Bullet Biotechnology, Inc. develops active immunotherapies to stimulate a person’s own immune system to overcome diseases. Its technology educates the immune system to targeting specific cells that are causing disease. The firm's pipeline includes therapeutic vaccines for cancer, multi-specific antibody capsid products, therapeutic vaccines for autoimmune diseases, and other vaccines. The company was founded by Diego Fonstad, James R. Swartz, Willie Quinn and Thomas Theriault in September 2011 and is headquartered in Redwood City, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Clive R. Wood | M | 63 |
University of London
| 8 years |
| Kang Bor Lee | M | 70 |
University of London
| 6 years |
| Penny Dash | M | - |
University of London
| 6 years |
| Maxim Webb | M | 63 |
University of London
| 4 years |
| Angie Gawreletz | F | - |
University of London
| 4 years |
| W. M. H. Jaim | M | - |
University of London
| 3 years |
| Timothy Wright | M | 63 |
University of London
| 3 years |
| Lim Beng Lin | M | 64 |
University of London
| 1 years |
| Richard Ian Woods | M | - |
University of London
| 4 years |
| Peter Davies | M | - |
University of London
| 4 years |
| Po Chuen Kwan | M | 65 |
University of London
| 3 years |
| Yong Ping Liu | M | 69 |
University of London
| 3 years |
| Andrew Neil McMellin | M | 58 |
University of London
| 3 years |
| Mark Vosloo | M | - |
University of London
| 4 years |
| Sabah Tayseer Barakat | M | 59 |
University of London
| 4 years |
| Ashley Alder | M | 65 |
University of London
| 3 years |
| Steve J. King | M | - |
University of London
| 4 years |
| Wing Cheung Wong | M | - |
University of London
| 3 years |
| Hugh F. Durrant-Whyte | M | - |
University of London
| 4 years |
| Michael George Holubowskyj | M | 58 |
University of London
| 4 years |
| William Taylor | M | - |
University of London
| 4 years |
| Emil Moskofian | M | - |
University of London
| 4 years |
| Man Shing Chi | M | 60 |
University of London
| 4 years |
| Rana Partap Chauhan | M | - |
University of London
| 7 years |
| Too Heng-Phon | M | 65 |
University of London
| 3 years |
| Lee Hui Chong | M | 48 |
University of London
| 4 years |
| Saheran Suhendran | M | 63 |
University of London
| 3 years |
| Chi Wang Lau | M | 76 |
University of London
| 4 years |
| Eiry Roberts | M | 60 |
University of London
| 3 years |
| Harikrishna Kulaveerasingam | M | 63 |
University of London
| 4 years |
| Zaini bin Omar | M | 74 |
University of London
| 3 years |
| Roger Bullock | M | - |
University of London
| 3 years |
| Uzir bin Abdul Malik | M | 79 |
University of London
| 3 years |
| Jayne O’Brien | F | - |
University of London
| 4 years |
| Natasha Foong | F | - |
University of London
| 3 years |
| Rateb Ahmed Ibrahim Al-Wazani | M | 92 |
University of London
| 3 years |
| John Soloninka | M | - |
University of London
| 2 years |
| Jaikrishna Patel | M | - |
University of London
| 4 years |
| Chris Poll | M | - |
University of London
| 3 years |
| Stewart James Jackson | M | 59 |
University of London
| 4 years |
| Wai Yip Tang | M | 66 |
University of London
| 4 years |
| Nik Ismail bin Nik Daud | M | 73 |
University of London
| 3 years |
| Mei Tjuen Tjioe | F | 66 |
University of London
| 4 years |
| Rachel Kyte | F | - |
University of London
| 3 years |
| Stelios Haji-Ioannou | M | 73 |
University of London
| 4 years |
| Harren Jhoti | M | 61 |
University of London
| 4 years |
| Suresh Yannamani | M | 59 |
University of London
| 4 years |
| Ka Kui Leung | M | 66 |
University of London
| 3 years |
| Arline Gaujal-Kempler | F | 73 |
University of London
| 3 years |
| Patrick Michael Round | M | 65 |
University of London
| 4 years |
| Doug Edwards | M | 64 |
University of London
| 3 years |
| Ignacio Sanín Bernal | M | 76 |
University of London
| 3 years |
| John-Mark Coates | M | 63 |
University of London
| 4 years |
| David Greening | M | - |
University of London
| 4 years |
| Ta Meng Tseng | M | 66 |
University of London
| 3 years |
| Siu Wah Chung | M | 67 |
University of London
| 3 years |
| Christopher Charles Warkup | M | - |
University of London
| 4 years |
| Andrew F. Moulder | M | - |
University of London
| 4 years |
| Marc R. Paul | M | - |
University of London
| 1 years |
| Vanessa K. Blackmore | F | - |
University of London
| 3 years |
| Ting Yeung Fok | M | 75 |
University of London
| 3 years |
| Ming Tung Ko | M | 63 |
University of London
| 3 years |
| Hon Tak Ng | M | 64 |
University of London
| 4 years |
| Timothy David Voake | M | - |
University of London
| 4 years |
| Alex Renny | M | 62 |
University of London
| 4 years |
| Peter Nolan | M | 75 |
University of London
| 3 years |
| Keith Starling | M | - |
University of London
| 3 years |
| Stephen Dilly | M | 64 |
University of London
| 3 years |
| William Morton Llewellyn | M | 59 |
University of London
| 4 years |
| Bing Hua Tan | M | 79 |
University of London
| 3 years |
| Wai Hin Choy | M | 61 |
University of London
| 4 years |
| Loga Bala Mohan Jaganathan | M | 58 |
University of London
| 3 years |
| Poh Tat Ng | M | 75 |
University of London
| 4 years |
| Pakhruddin bin Sulaiman | M | 67 |
University of London
| 3 years |
| Nigel Raymond Stevenson | M | - |
University of London
| 3 years |
| Paul Castella | M | - |
University of London
| 3 years |
| King Yan To | M | 65 |
University of London
| 3 years |
| Chee Keong Tan | M | - |
University of London
| 4 years |
| Tan Chee Keong | M | - |
University of London
| 4 years |
| Ka Hing Wong | M | 63 |
University of London
| 4 years |
| Kian Min Ong | M | 63 |
University of London
| 3 years |
| Gordon Ng | M | 59 |
University of London
| 4 years |
| Carmelo Furci | M | 71 |
University of London
| 3 years |
| Siak Hee Tan | M | 69 |
University of London
| 4 years |
| Naimah binti Abdul Khalid | F | 66 |
University of London
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 85 | 85.00% |
| Switzerland | 8 | 8.00% |
| United States | 5 | 5.00% |
| Canada | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hari Kumar
- Personal Network
